

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virginia 22313-1450 www.msyolo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/328,742	06/06/1999	ALEXANDROS MAKRIYANNIS	UCON/141/US	7228
2543 7590 12/90/2099 ALIX YALE & RISTAS LLP 750 MAIN STREET			EXAMINER	
			PRYOR, ALTON NATHANIEL	
SUITE 1400 HARTFORD,	CT 06103		ART UNIT	PAPER NUMBER
			MAIL DATE	DELIVERY MODE
			12/30/2009	PAPER

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# Application No. Applicant(s) 09/328,742 MAKRIYANNIS ET AL. Office Action Summary Examiner Art Unit ALTON N. PRYOR 1616 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 27 August 2009. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 24.25 and 27-34 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) \_\_\_\_\_ is/are allowed. 6) Claim(s) 25 and 27-34 is/are rejected. 7) Claim(s) 24 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner, Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some \* c) ☐ None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date. \_\_\_ Notice of Draftsperson's Patent Drawing Review (PTO-948)

Paper No(s)/Mail Date

Information Disclosure Statement(s) (PTO/SE/03)

5) Notice of Informal Patent Application

6) Other:

Application/Control Number: 09/328,742 Page 2

Art Unit: 1616

#### DETAILED ACTION

Applicant's arguments, see paper, filed 8/27/09, with respect to the rejection(s) of claim(s) under obviousness type Double Patenting have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection made below.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 25,27-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Beltramo et al. (Anandamide transport inhibition by the vanilloid agonist olvanil, European Journal of Pharmacology 364, 1999, 75-78). Beltramo et al. teach method of using N--(4-hydroxyphenyl)-arachidonylamide (AM404) to control anandamide transportation. Beltramo et al. do not teach a method of applying the composition to an individual. However, it would have been obvious to administer AM404 to an individual. One would have been motivated to do this since the preliminary in-vitro studies are followed by in-vivo studies.

Claims 25,27-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Street et al. (Slow- and Tight- Binding Inhibitors of the 85-kDa Human Phospholipase A2, Biochemistry, 32, 1993, 5935-40). Street et al. teach method of using arachidonylamide to control anandamide transportation. Street et al. do not teach a Art Unit: 1616

method of applying the composition to an individual. However, it would have been obvious to administer arachidonylamide to an individual. One would have been motivated to do this since the preliminary in-vitro studies are followed by in-vivo studies.

### Allowable Subject Matter

Claim 24 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The prior art does teach or suggest the administration of the compounds in claim 24 to an individual.

### Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALTON N. PRYOR whose telephone number is (571)272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/328,742 Page 4

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Alton N. Pryor/ Primary Examiner, Art Unit 1616